Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nipro Markets Human iPS Cell Products To Pharmaceutical Companies In Japan

This article was originally published in PharmAsia News

Executive Summary

Japanese drug and device maker Nipro June 1 launched cardiomyocytes made from induced pluripotent stem cells to research institutions and pharmaceutical companies for cardiac research and new drug development. The first commercial products made from human iPS cells in Japan, the cardiomyocytes are manufactured by Tokyo-based biotech venture company ReproCell. Nipro signed a licensing agreement and obtained exclusive rights in Japan. Priced at ¥300,000 each kit consists of five cell clusters, Nipro estimates ¥20-¥50 million in annual sales. The cardiotoxicity assay allows the direct measurement of parameters in an invitro functional assay that comes close to invivo conditions. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts